TheraRadar
← Back
Data updated: Mar 29, 2026

Amgen

AMGN
OncologyImmunologyMetabolic
Biotech

Pioneer biotechnology company with strength in oncology and inflammation. Known for biologics innovation including Enbrel, Repatha, and biosimilar portfolio.

$33.4B
Revenue (2024)
$155.0B
Market Cap
-
Trials
48
Approved (2yr)

Key Drugs

REPATHA
evolocumab
PCSK9 4 indications · 2015
OTEZLA
apremilast
PDE4 4 indications · 2014
OTEZLA XR
apremilast
Immunology
PDE4 3 indications · 2025
BLINCYTO
blinatumomab
Oncology
CD19 1 indications · 2014
LUMAKRAS
sotorasib
KRAS G12C 2 indications · 2021

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Competitive Matchups Pro

Loading...

Recent Activity

OTEZLA 2025-12-23
Labeling
BKEMV 2025-11-24
Labeling
IMDELLTRA 2025-11-19
Efficacy
BLINCYTO 2025-10-21
Labeling
AMJEVITA 2025-10-16
WEZLANA 2025-09-25
Labeling
WEZLANA 2025-09-25
Labeling
BKEMV 2025-09-17
REMS
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 44%
9 drugs Phase 3: 25 Phase 2: 15 Phase 1: 70
Immunology 26%
6 drugs Phase 3: 19 Phase 2: 13 Phase 1: 13
Metabolic 15%
0 drugs Phase 3: 15 Phase 2: 4 Phase 1: 20
Gastroenterology 8%
4 drugs Phase 3: 2 Phase 2: 3 Phase 1: 8
Neurology 7%
1 drugs Phase 3: 6 Phase 2: 2 Phase 1: 9

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Takeda big-pharma
Immunology, Oncology, Gastroenterology, Neurology, Metabolic
Eli Lilly big-pharma
Metabolic, Oncology, Immunology, Neurology
EMD SERONO INC biotech
Oncology, Neurology, Immunology, Metabolic, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Gastroenterology, Neurology
Pfizer big-pharma
Oncology, Immunology, Gastroenterology